We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+6.83%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$1.32B
AUM Growth
-$100M
(-7%)
Cap. Flow
-$118M
Cap. Flow
% of AUM
-8.94%
Top 10 Holdings %
Top 10 Hldgs %
27.68%
Holding
135
New
38
Increased
26
Reduced
44
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OCDX
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
|
+$30.5M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$27.4M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
+$26.1M |
| 4 |
ACCD
Accolade Inc
ACCD
|
+$22.7M |
| 5 |
Vor Biopharma
VOR
|
+$22.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tandem Diabetes Care
TNDM
|
+$40.6M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$35M |
| 3 |
Exelixis
EXEL
|
+$29.6M |
| 4 |
Labcorp
LH
|
+$28.8M |
| 5 |
AFIB
Acutus Medical Inc
AFIB
|
+$28.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.61% |
| 2 | Industrials | 3.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Nkarta
NKTX
$154M
| $5.56M | 0.42% |
+169,050
| New | +$8.08M |
|
77
Amgen
AMGN
$204B
| $5.3M | 0.4% |
21,303
-1,150
| -5% | -$274K |
|
|
TLIS
78
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
| $5.21M | 0.39% |
+27,006
| New | +$6.74M |
|
|
BLU
79
DELISTED
BELLUS Health Inc.
BLU
| $4.9M | 0.37% |
1,274,940
-422,000
| -25% | -$1.6M |
|
80
Thermo Fisher Scientific
TMO
$213B
| $4.75M | 0.36% |
10,400
| – | – |
|
|
ONCR
81
DELISTED
Oncorus, Inc.
ONCR
| $4.66M | 0.35% |
+335,000
| New | +$6.94M |
|
82
Boston Scientific
BSX
$72B
| $3.97M | 0.3% |
102,726
+52,500
| +105% | +$1.99M |
|
83
Danaher
DHR
$139B
| $3.78M | 0.29% |
18,922
+10,462
| +124% | +$2.12M |
|
84
Biogen
BIIB
$29.8B
| $3.49M | 0.26% |
12,482
-300
| -2% | -$80.9K |
|
85
CryoPort
CYRX
$781M
| $3.49M | 0.26% |
+67,034
| New | +$4.08M |
|
86
Stryker
SYK
$131B
| $3.34M | 0.25% |
13,700
+5,900
| +76% | +$1.41M |
|
87
Pfizer
PFE
$143B
| $3.17M | 0.24% |
87,400
-7,500
| -8% | -$266K |
|
|
88
Tandem Diabetes Care
TNDM
$1.38B
| $3.1M | 0.23% |
35,100
-436,718
| -93% | -$40.6M |
|
89
Personalis
PSNL
$1.41B
| $2.97M | 0.22% |
+120,500
| New | +$4.13M |
|
90
Vertex Pharmaceuticals
VRTX
$119B
| $2.43M | 0.18% |
11,321
-5,600
| -33% | -$1.23M |
|
91
Cytosorbents Corp
CTSO
$23.1M
| $2.37M | 0.18% |
272,660
-832,275
| -75% | -$7.93M |
|
92
Sotera Health
SHC
$5.13B
| $2.26M | 0.17% |
90,368
+15,750
| +21% | +$417K |
|
93
Regeneron Pharmaceuticals
REGN
$78.2B
| $2.19M | 0.17% |
4,620
| – | – |
|
94
Moderna
MRNA
$21.9B
| $2.08M | 0.16% |
15,850
-110,456
| -87% | -$16M |
|
|
ONC
95
BeOne Medicines Ltd
ONC
$32.6B
| $2.02M | 0.15% |
+5,800
| New | +$1.92M |
|
96
Gilead Sciences
GILD
$163B
| $1.89M | 0.14% |
29,250
-300
| -1% | -$19.3K |
|
97
Illumina
ILMN
$30B
| $1.6M | 0.12% |
4,276
+92
| +2% | +$37.5K |
|
98
Zai Lab
ZLAB
$2.05B
| $787K | 0.06% |
5,900
+2,000
| +51% | +$310K |
|
99
Incyte
INCY
$24B
| $667K | 0.05% |
8,210
-430
| -5% | -$36.7K |
|
|
GBIO
100
DELISTED
Generation Bio
GBIO
| $613K | 0.05% |
+2,152
| New | +$689K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
TGM
BIS
Sectoral Asset Management's Q1 2021 Portfolio in Review
As of Q1 2021, Sectoral Asset Management held 135 positions worth $1.32B, down 7% from $1.42B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Sectoral Asset Management withdrew a net $118M in Q1 2021, closing 22 positions and reducing 44 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $35M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Industrials.
Against the trend, Sectoral Asset Management opened a new position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares worth $33.4M.
- Sectoral Asset Management's largest Q1 2021 buy was Ortho Clinical Diagnostics Holdings plc Ordinary Shares: 1,730,500 shares worth $33.4M.
- Sectoral Asset Management added most to TG Therapeutics in Q1 2021, an estimated $14.8M increase.
- Sectoral Asset Management's biggest Q1 2021 reduction was Tandem Diabetes Care, cutting an estimated $40.6M.
- Sectoral Asset Management fully exited Acadia Pharmaceuticals in Q1 2021, selling an estimated $35M.
- Sectoral Asset Management's ten largest holdings make up 28% of its $1.32B portfolio in Q1 2021.
- Sectoral Asset Management opened 38 new positions and closed 22 in Q1 2021.
- Sectoral Asset Management's portfolio value fell 7% quarter-over-quarter to $1.32B.
Based on Sectoral Asset Management's 13F filing for Q1 2021, filed 14 May 2021.